<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106184</url>
  </required_header>
  <id_info>
    <org_study_id>N01 AR042273</org_study_id>
    <secondary_id>5R01AR061298-02</secondary_id>
    <secondary_id>HHSN26420042273C</secondary_id>
    <nct_id>NCT00106184</nct_id>
    <nct_alias>NCT00393237</nct_alias>
  </id_info>
  <brief_title>Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)</brief_title>
  <official_title>Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab is a man-made antibody used to treat certain types of cancer. This study will
      determine whether rituximab is an effective treatment for adult and pediatric patients with
      dermatomyositis or polymyositis.

      Study hypotheses: 1) The time to improvement in Group A patients (receiving rituximab first)
      will occur significantly earlier than in Group B patients (receiving rituximab later). 2) The
      proportion of patients improved at Week 8 of the treatment phase will be significantly
      greater in Group A than in Group B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed
      against the CD20 (cluster of differentiation antigen 20) antigen found on the surface of
      B-lymphocytes and is known to deplete B cells when administered intravenously. It is approved
      to treat non-Hodgkin's lymphoma. Rituximab has been used for autoimmune diseases such as
      systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and immune-mediated
      hematologic disorders. It has also been studied and used in small numbers of patients with
      myositis. This study will evaluate the efficacy of rituximab in treating refractory adult and
      pediatric patients with dermatomyositis and adult polymyositis.

      A patient's participation in this study will last approximately 45 weeks. At screening,
      participants will have a physical exam, muscle strength assessment, an electrocardiogram, and
      blood and urine collection; they will also be asked to complete several questionnaires. All
      participants will receive 2 infusions of rituximab and 2 infusions of placebo. Participants
      will be randomly assigned to one of two groups. Group A will receive rituximab at Weeks 0 and
      1 and placebo at Weeks 8 and 9. Group B will receive placebo at Weeks 0 and 1 and rituximab
      at Weeks 8 and 9. Each infusion will be given on an outpatient basis over a minimum of
      approximately 5 hours' time.

      There will be a total of 14 study visits. All participants will visit the outpatient clinic
      at selected time points for muscle strength testing, a physical exam, disease activity
      measurements, and blood collection. During the study, participants will be monitored closely
      for improvement or worsening of their disease and for serious drug related side effects. Some
      participants will be asked if they are willing to undergo 2 muscle biopsy procedures, 1 prior
      to receiving study medication and 1 after receiving study medication, to determine the
      effects of rituximab on muscle tissue.

      If a participant is unable to locate a near-by clinical center, the adult and pediatric
      centers at the National Institute of Health located in Bethesda, Maryland have funds
      available to assist with travel costs.

      NIH SUB-STUDY: &quot;Rituximab to Treat Dermatomyositis and Polymyositis&quot;

        -  This study is currently recruiting patients.

        -  Sponsored by: National Institute of Environmental Health Sciences (NIEHS)

        -  Information provided by: National Institutes of Health Clinical Center (CC)

        -  Expected Total Enrollment: 30

        -  Study start: October 2006

        -  Location and Contact Information: Patient Recruitment and Public Liaison Office;(800)
           411-1222; prpl@mail.cc.nih.gov; Phone: 1-866-411-1010

      The NIH sub-study will take advantage of the multi-center core RIM trial to identify changes
      in gene expression patterns in muscle, skin, and peripheral blood and the imaging features
      and immunopathology of muscle, skin, and peripheral cells before (week 0) and after (week 16)
      therapy. These changes will also be correlated with the large number of clinical, laboratory,
      and research variables already planned to be collected in the core RIM Study. Furthermore,
      knowing specifically which gene expression patterns are altered in resistant patients before
      rituximab, and which are changed after rituximab therapy - in conjunction with flow cytometry
      of peripheral cells and immunopathology of the tissues - will help in understanding more
      about the pathogenesis of myositis and the possible contribution of B lymphocytes and their
      subsets.

      Patients with dermatomyositis and polymyositis who meet the inclusion/exclusion criteria for
      the core RIM trial may be eligible for this sub-study. The following procedures will be
      conducted in addition to the core RIM trial procedures during the 13 clinic visits over a
      period of 44 weeks:

        -  Weeks 0, 16: Muscle and skin biopsy (adult only). Small samples of muscle and skin
           tissue will be surgically removed for examination under a microscope.

        -  Weeks 0, 8, 16, 44: Skin evaluation and photography. The effect of the disease on the
           skin will be thoroughly evaluated and photographs of any rashes and of the skin around
           the nails will be taken.

        -  Weeks 0, 8, 16, 44: Magnetic resonance imaging (MRI). All participants will have MRI
           scans of the skin and of the muscle in the legs. Adults will also have an MRI to examine
           blood flow in the muscle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients</measure>
    <time_frame>Week 44 of treatment phase</time_frame>
    <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8</measure>
    <time_frame>Week 8 of the treatment phase</time_frame>
    <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])</measure>
    <time_frame>Week 44 of treatment phase</time_frame>
    <description>Number of participants with a 20% improvement in MMT over baseline on two consecutive time points.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Myositis</condition>
  <condition>Dermatomyositis</condition>
  <condition>Polymyositis</condition>
  <condition>Juvenile Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Adult Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Study Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JDM Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JDM Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9</description>
    <arm_group_label>Adult Study Group 1</arm_group_label>
    <arm_group_label>Adult Study Group 2</arm_group_label>
    <arm_group_label>Adult Study Group 3</arm_group_label>
    <arm_group_label>Adult Study Group 4</arm_group_label>
    <arm_group_label>JDM Study Group 1</arm_group_label>
    <arm_group_label>JDM Study Group 2</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment Group A: placebo infusion at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
    <arm_group_label>Adult Study Group 1</arm_group_label>
    <arm_group_label>Adult Study Group 2</arm_group_label>
    <arm_group_label>Adult Study Group 3</arm_group_label>
    <arm_group_label>Adult Study Group 4</arm_group_label>
    <arm_group_label>JDM Study Group 1</arm_group_label>
    <arm_group_label>JDM Study Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with definite or probable dermatomyositis or polymyositis and pediatric
             patients five years of age and over with definite or probable juvenile dermatomyositis
             (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e.,
             first symptom of myositis or dermatomyositis rash) is less 18 years of age

          -  Refractory myositis, defined by intolerance to or inadequate response to
             corticosteroids plus an adequate regime of at least one other immunosuppressive agent.
             Intolerance is defined as side effects that require discontinuation of the medication
             or an underlying condition that precludes further use of the medication.

          -  Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test)
             score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a
             score that is no greater than 125/150 in conjunction with 2 other abnormal core set
             measures.

        Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the
        following criteria:

          1. An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction
             with 2 other abnormal core set measures.

             OR

          2. If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at
             least 3 abnormal core set measures.

               -  Background therapy with at least 1 non-corticosteroid immunosuppressive agent at
                  a stable dose for at least 6 weeks prior to screening

               -  Able and willing to complete self-report questionnaires. Parents of pediatric
                  participants will be required to complete the questionnaires on behalf of their
                  children.

               -  Willing to use acceptable forms of contraception for the duration of the study
                  for patients of reproductive potential.

               -  Parent willing to provide informed consent, if applicable

               -  Willing to forgo immunization with a live vaccine for the duration of the study

        Exclusion Criteria:

          -  Drug-induced myositis. Patients who have myositis or myopathic syndromes caused by
             taking medications known to induce myositis-like syndromes, including but not limited
             to statin agents, fibric acid derivatives, colchicine, and hydroxychloroquine.

          -  Juvenile polymyositis

          -  Inclusion body myositis

          -  Cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the
             diagnosis of cancer. Patients with basal or squamous cell skin cancer or carcinoma in
             situ of the cervix are not excluded, if it has been at least 5 years since excision.

          -  Myositis in overlap with another connective tissue disease that may preclude the
             accurate assessment of a treatment response

          -  Live viral vaccine within 4 weeks prior to study entry

          -  Any joint disease or other musculoskeletal condition that may interfere with muscle
             strength testing

          -  Known hypersensitivity to mouse proteins

          -  Any concomitant or life-threatening non-myositis illness that, in the opinion of the
             investigator, may interfere with the study

          -  Known or suspected history of drug or alcohol abuse within the last 6 months prior to
             study entry, as determined by medical record or patient interview

          -  Anticipated poor compliance with study requirements

          -  Participation in another clinical trial within 30 days prior to screening

          -  Any history or evidence of any severe illness or other condition that, in the opinion
             of the investigator, may interfere with the study

          -  Previously received rituximab

          -  Evidence of prior infection with hepatitis B or hepatitis C virus

          -  Initiation of an exercise program within 4 weeks of screening OR initiation of an
             exercise program during the study

          -  Consumed any creatine-containing, over-the-counter products in the form of dietary
             supplements 30 days prior to screening visit and for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chester V. Oddis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann M. Reed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Arthritis Intervention Program (Adult Site)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Neurological Associates, LTD (Adult Site)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center (Adult Site)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University (Adult Site)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University (Pediatric Site)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine (Adult Site)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital (Pediatric Site)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (Adult Site)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Clinic (Adult Site)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Health (Adult Site)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Health (Pediatric Site)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston (Pediatric Site)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Adult Site)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System (Adult Site)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University (Adult and Pediatric Site)</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Adult Site)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Pediatric Site)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System (Adult Site)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery (Adult Site)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (Pediatric Site)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati's Children's Hospital (Pediatric Site)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (Pediatric Site)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (Adult Site)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh (Pediatric Site)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh / UPMC (Adult Site)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center (Adult)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin / Froedtert Memorial Luthern Hospital (Adult Site)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children (Pediatric Site)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.myositis.org</url>
    <description>Click here for the Myositis Association Web site</description>
  </link>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_07-E-0012.html@myositis</url>
    <description>Click here for the NIH Clinical Center (sub-study)</description>
  </link>
  <reference>
    <citation>Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol. 2001 Jun;54(6):550-7.</citation>
    <PMID>11377114</PMID>
  </reference>
  <reference>
    <citation>Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005 Feb;52(2):601-7.</citation>
    <PMID>15692974</PMID>
  </reference>
  <results_reference>
    <citation>Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.</citation>
    <PMID>23124935</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2005</study_first_submitted>
  <study_first_submitted_qc>March 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2005</study_first_posted>
  <results_first_submitted>October 10, 2013</results_first_submitted>
  <results_first_submitted_qc>March 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2015</results_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Chester Oddis</investigator_full_name>
    <investigator_title>MD, Professor of Medicine, University of Pittsburgh, Division of Rheumatology and Clinical Immunology</investigator_title>
  </responsible_party>
  <keyword>rituximab</keyword>
  <keyword>myositis</keyword>
  <keyword>dermatomyositis</keyword>
  <keyword>polymyositis</keyword>
  <keyword>refractory</keyword>
  <keyword>Juvenile Dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject were screened and enrolled at 26 US and 4 international sites.</recruitment_details>
      <pre_assignment_details>In an effort to exclude IBM (Inclusion Body Myositis) and other myositis mimics, the medical records and muscle biopsy results (if available) of adults with PM were reviewed by a 3-member Adjudication Committee before enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group A (Rituximab Wks 0 and 1)</title>
          <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group B (Rituximab Wks 8 and 9)</title>
          <description>Subjects received placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="93">96 subjects were randomized.</participants>
                <participants group_id="P2" count="102">104 subjects were randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 subjects in Group A and 2 subjects in Group B were excluded from analysis due to withdrawing from the study. These subjects either did not receive a full dose of study drug at week 0 or no study drug at all.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA up to a maximum dose of 1 gram at Weeks 0 and 1
Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Subjects received placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="18.23"/>
                    <measurement group_id="B2" value="40.7" spread="18.4"/>
                    <measurement group_id="B3" value="41.8" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients</title>
        <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
        <time_frame>Week 44 of treatment phase</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Rituximab Wks 0 and 1)</title>
            <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA up to a maximum dose of 1 gram at Weeks 0 and 1
Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
          </group>
          <group group_id="O2">
            <title>Group B (Rituximab Wks 8 and 9)</title>
            <description>Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients</title>
          <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
          <population>Intention to Treat (ITT)</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="8" upper_limit="44"/>
                    <measurement group_id="O2" value="20.0" lower_limit="8" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportional hazards model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.74</p_value>
            <method>Log Rank</method>
            <method_desc>No confidence intervals as no parameters were estimated.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8</title>
        <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
        <time_frame>Week 8 of the treatment phase</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group A (Rituximab Wks 0 and 1)</title>
            <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA up to a maximum dose of 1 gram at Weeks 0 and 1 Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group B (Rituximab Wks 8 and 9)</title>
            <description>Subjects received placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8</title>
          <description>The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures.
Core Set Measures Included:
Manual Muscle Testing (MMT)- Muscle Strength
Physician Global Disease Activity VAS Score
Health Assessment Questionnaire Index Score - Physical Function
Patient Global Assessment of Disease Activity VAS score
Extramuscular Activity - Myositis Disease Activity Assessment Tool
2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)</description>
          <population>Intention to Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.90</p_value>
            <method>Chi-squared</method>
            <method_desc>Difference in baseline muscle enzymes therefore tested the difference in the proportions adjusting for the baseline values.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])</title>
        <description>Number of participants with a 20% improvement in MMT over baseline on two consecutive time points.</description>
        <time_frame>Week 44 of treatment phase</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group A (Rituximab Wks 0 and 1)</title>
            <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA up to a maximum dose of 1 gram at Weeks 0 and 1 Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group B (Rituximab Wks 8 and 9)</title>
            <description>Subjects received placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
          </group>
        </group_list>
        <measure>
          <title>20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])</title>
          <description>Number of participants with a 20% improvement in MMT over baseline on two consecutive time points.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.90</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported Adverse Events (AEs) include events starting on or after Week 0 and on or before Week 44 of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group A</title>
          <description>Subjects received rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Rituximab : Treatment Group A - intravenous rituximab 750mg/m2 BSA up to a maximum dose of 1 gram at Weeks 0 and 1 Placebo : Treatment Group A: placebo infusion at Weeks 8 and 9</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group B</title>
          <description>Subjects received placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Group B - intravenous rituximab 750mg/m2 BSA up to a maximum does of 1 gram at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia die to esophageal ulcers</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ischemia/myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Clostridium Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Joint Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness - Disease Flare</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Disorder - Aseptic Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Raynaud Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Death - Cerebral Vascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was an overestimate of the rapidity of the rituximab response and an underestimate of DOI in those receiving placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chester V. Oddis, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-383-8861</phone>
      <email>cvo5@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

